Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy E G Krueger

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Frontiers in Immunology|February 21, 2015
Augmenting antitumor immune responses with epigenetic modifying agentsErika Héninger, Timothy E G Krueger, Joshua M Lang
Stem Cells Translational Medicine|August 3, 2018
Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the PromiseTimothy E G Krueger, Daniel L J Thorek, Samuel R Denmeade, et al.
Neoplasia (New York, N.Y.)|August 8, 2022
Targeting interleukin 4 receptor alpha on tumor-associated macrophages reduces the pro-tumor macrophage phenotypeAmber E de Groot, Kayla V Myers, Timothy E G Krueger, et al.
Oncotarget|October 22, 2016
Inducible expression of cancer-testis antigens in human prostate cancerErika Heninger, Timothy E G Krueger, Stephanie M Thiede, et al.
Communications Biology|September 1, 2022
Reversible epigenetic alterations regulate class I HLA loss in prostate cancerTamara S Rodems, Erika Heninger, Charlotte N Stahlfeld, et al.
The Prostate|May 5, 2021
Characterization of tumor-associated macrophages in prostate cancer transgenic mouse modelsAmber E de Groot, Kayla V Myers, Timothy E G Krueger, et al.
The Prostate|April 15, 2024
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical modelsSumer Jasmine, Adel Mandl, Timothy E G Krueger, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|February 21, 2015
Augmenting antitumor immune responses with epigenetic modifying agentsErika Héninger, Timothy E G Krueger, Joshua M Lang
Stem Cells Translational Medicine|August 3, 2018
Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the PromiseTimothy E G Krueger, Daniel L J Thorek, Samuel R Denmeade, et al.
Neoplasia (New York, N.Y.)|August 8, 2022
Targeting interleukin 4 receptor alpha on tumor-associated macrophages reduces the pro-tumor macrophage phenotypeAmber E de Groot, Kayla V Myers, Timothy E G Krueger, et al.
Oncotarget|October 22, 2016
Inducible expression of cancer-testis antigens in human prostate cancerErika Heninger, Timothy E G Krueger, Stephanie M Thiede, et al.
Communications Biology|September 1, 2022
Reversible epigenetic alterations regulate class I HLA loss in prostate cancerTamara S Rodems, Erika Heninger, Charlotte N Stahlfeld, et al.
The Prostate|May 5, 2021
Characterization of tumor-associated macrophages in prostate cancer transgenic mouse modelsAmber E de Groot, Kayla V Myers, Timothy E G Krueger, et al.
The Prostate|April 15, 2024
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical modelsSumer Jasmine, Adel Mandl, Timothy E G Krueger, et al.
Pageof 1